Home » News » Conference Coverage » American Society of Clinical Oncology (ASCO) » ASCO 2020 » ASCO 2020 HCC In-Depth
ASCO 2020 HCC In Depth
ASCO 2020 HCC In-Depth A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.
Noninvasive method could help monitor treatment responses.
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.
Load More
Open
Next post in ASCO 2020 HCC In-Depth
Close
Close more info about Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
Loading...
Close more info about Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
Loading...